Items where Division is "Current Faculties > Faculty of Medicine > Cancer Sciences > Immunology > Antibody and Vaccine Group
Cancer Sciences > Immunology > Antibody and Vaccine Group" and Year is 2026
 | Up a level |
Number of items: 6.
Current treatment strategies for first relapse of high-risk neuroblastoma - Sveva Castelli, Franziska Schulze and Theresa M. Thole-Kliesch
Type: Article
| 2026
CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A - Lara V. Graham, Russell B. Foxall, Margaret Ashton-Key, Salim I. Khakoo, Souraya Sayegh, Maria Leandro, Venkat R. Reddy, Mark S. Cragg and Matthew D. Blunt
Type: Article
| 2026
Type: Dataset
| 2026
| University of Southampton
| Item availability restricted.
The efficacy and safety of bevacizumab/irinotecan/temozolomide (BIT) for relapsed/refractory neuroblastoma: the UK Children’s Cancer and Leukaemia Group experience - Thomas J. Jackson, Menna Shamma and Upeka Senanayake
Type: Article
| 2026
Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons - Holger N. Lode, Przemysław Holko, Aleksandra Wieczorek, Katarzyna Sladowska, Nikolai Siebert, Dominique Valteau-Couanet, Alberto Garaventa, Adela Cañete, John Anderson, Isaac Yaniv, Shifra Ash, Lucas Moreno, Juliet Gray, Roberto Luksch, Genevieve Laureys, Cormac Owens, Carla Manzitti, Sascha Troschke-Meurer, Paweł Kawalec and Ruth L. Ladenstein
Type: Article
| 2026
Reply to: a signal worth trusting—if we can reproduce it: clarifying ORR and PFS in BEACON immuno - Lucas Moreno, Simon Gates, rebekah weston and Juliet Gray
Type: Letter
| 2026
| Item availability restricted.